Why Farbe Firma is the Top Manufacturer of Gadoterate Meglumine Injection
- Maulik Sudani
- 1 day ago
- 9 min read
Last Updated: July 6, 2026
TL;DR: Gadoterate Meglumine Injection - a sterile aqueous solution of gadoteric acid formulated as its meglumine (N-methylglucamine) salt, a macrocyclic and ionic gadolinium-based contrast agent (GBCA) in which the paramagnetic gadolinium(III) ion is locked inside the cage-like DOTA macrocyclic ligand, supplied at 0.5 mmol/mL (about 279.3 mg/mL) in glass vials and pre-filled syringes for intravenous injection - is the MRI contrast medium radiologists rely on to brighten tissue on T1-weighted magnetic-resonance imaging of the brain and spine, the blood vessels and the whole body. Because a paramagnetic heavy-metal complex is injected into a vein purely to sharpen a diagnostic image, every unit must deliver a sterile, correctly complexed, very-low-free-gadolinium solution held at the right osmolality and pH, with the gadoterate assay, the free (uncomplexed) gadolinium and free macrocyclic ligand, the osmolality and pH, colour and clarity, particulate matter and a low endotoxin level, a validated terminal sterilisation and verified container-closure integrity all mattering to image quality and patient safety. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Gadoterate Meglumine Injection at our Gujarat, India facility and supplies it to radiology, diagnostic-imaging, hospital and imaging-centre services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Macrocyclic gadolinium-based MRI contrast agent - gadoterate meglumine is the meglumine salt of gadoteric acid, an ionic complex in which a paramagnetic gadolinium(III) ion is held inside the cage-like DOTA macrocyclic ligand; given intravenously it shortens the T1 relaxation time of nearby water protons and brightens tissue on T1-weighted MRI, and Gadoterate Meglumine Injection (a 0.5 mmol/mL aqueous solution given intravenously) demands a correctly complexed, very-low-free-gadolinium, sterile solution in every vial and pre-filled syringe.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated compounding and vial and pre-filled-syringe filling, control of the gadoterate assay and of free (uncomplexed) gadolinium and free macrocyclic ligand by validated methods, osmolality, pH, colour and clarity, particulate and endotoxin, validated terminal moist-heat sterilisation, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, free-gadolinium and free-ligand control data, sterilisation and container-closure data, forced-degradation data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and diagnostic-imaging tenders.
End-to-end CDMO services: Sterile gadolinium-contrast-agent vial and pre-filled-syringe contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets with dose-by-body-weight and renal-function guidance, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why the Right Gadoterate Meglumine Injection Manufacturer Matters
Gadoterate Meglumine Injection has become one of the most widely trusted contrast media in diagnostic magnetic-resonance imaging. It is the agent a radiologist turns to when a scan needs contrast enhancement - to define a brain tumour or metastasis, to characterise a multiple-sclerosis plaque, to study the spine, to map blood vessels in MR angiography, or to assess soft-tissue and whole-body disease. Gadoterate is a gadolinium-based contrast agent: the useful atom is gadolinium(III), a strongly paramagnetic lanthanide that shortens the T1 relaxation time of the water protons around it, so tissue that takes up the agent lights up brightly on a T1-weighted image. Free gadolinium ions are toxic, however, so the metal is never given alone - it is wrapped inside a chelating ligand that holds it as a stable, water-soluble complex that circulates and is cleared by the kidneys without releasing the metal. What makes gadoterate distinctive among these agents is its chemistry: it is both macrocyclic and ionic, meaning the gadolinium sits inside a pre-organised, cage-like DOTA ring rather than an open chain, which gives it the highest thermodynamic and kinetic stability of any marketed class and places it among the agents considered to have the lowest risk of releasing free gadolinium in the body.
That clinical reality places real demands on the manufacturer. Gadoterate Meglumine Injection is presented as a ready-to-use sterile aqueous solution at a strength of 0.5 mmol/mL - about 279.3 mg of gadoterate meglumine per millilitre - filled into glass vials of 5, 10, 15 and 20 mL and, increasingly, into pre-filled syringes, and given intravenously at a weight-based dose of 0.1 mmol per kilogram (0.2 mL/kg) for most indications. Because the whole clinical value of the product is a stable metal complex that does not shed its gadolinium, the defining quality attribute is the control of free, uncomplexed gadolinium and of free macrocyclic ligand: the assay must confirm the labelled gadoterate content, and validated methods must show that uncomplexed gadolinium is held to a very low limit across the shelf life. The solution is markedly hyperosmolar relative to blood, so its osmolality and viscosity are controlled and stated; the pH is held in a defined window; and the solution must be clear, essentially colourless to pale yellow, and free of visible and sub-visible particulate. Because gadoterate meglumine in aqueous solution is heat-stable, the filled containers are generally terminally sterilised by a validated moist-heat cycle, which gives the highest sterility assurance, with bacterial endotoxin held very low for an intravenous diagnostic and container-closure integrity assured. Choosing a Gadoterate Meglumine Injection manufacturer that treats free-gadolinium control, complex assay accuracy and validated sterilisation as core disciplines is what protects the patient at the point of care.
What Sets a World-Class Gadoterate Meglumine Injection Manufacturer Apart
A world-class manufacturer of Gadoterate Meglumine Injection invests in three areas that weaker suppliers underfund: precise, validated control of the gadoterate assay and of free (uncomplexed) gadolinium and free macrocyclic ligand - the attributes that prove the metal is safely caged and that the labelled contrast strength is delivered; disciplined osmolality, pH, particulate and endotoxin control, because a hyperosmolar heavy-metal complex injected intravenously for diagnosis must be exactly complexed, clear and very low in endotoxin; and tender-ready dossier support, including the free-gadolinium, sterilisation and stability data, for a contrast agent procured through radiology, hospital-formulary and ministry-of-health channels. It starts with the raw materials - high-purity gadolinium oxide, the macrocyclic DOTA ligand and meglumine, each of controlled purity and metal-impurity profile - sourced from qualified, audited suppliers with full certificates of analysis verified by the receiving laboratory before the material enters production. Because the value of the product is a precise, stable, fully complexed, very-low-free-gadolinium dose of a sterile diagnostic, the complex assay, the free-gadolinium level, the endotoxin and the sterility assurance are treated as central evidence rather than supporting annexes.
Compounding and filling then have to build - and defend - a correctly complexed, low-free-metal, sterile solution. The gadolinium and the DOTA ligand are combined so that essentially all of the metal is chelated, with the complexation controlled so that free gadolinium is driven to a very low level; the meglumine forms the soluble salt, the pH and osmolality are set into their defined windows, and the bulk solution is polished by filtration to remove particulate. The solution is passed through a sterilising-grade filter and filled into glass vials or pre-filled syringes under ISO Class 5 conditions, the containers sealed and then terminally sterilised by a validated moist-heat cycle locked into the master batch record, giving a robust sterility assurance level for the aqueous solution. Filled units are 100% inspected for fill, seal, clarity, colour and particulate; in-process and release testing confirm the gadoterate assay, the free (uncomplexed) gadolinium and free macrocyclic ligand, the osmolality, the pH, the colour and clarity against defined limits, visible and sub-visible particulate matter, the deliverable volume, and that endotoxin is held well within limits so the solution is safe for intravenous use. Because the product is a diagnostic heavy-metal complex, the assay and the free-gadolinium level are confirmed before and after the sterilisation cycle, so the solution that leaves the plant is the same stable, fully caged, in-specification contrast agent the specification requires - with no loss of complex integrity and no free-gadolinium drift in the container across shelf life.
Quality Systems Behind Every Gadoterate Meglumine Injection
Every Farbe Firma Gadoterate Meglumine Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of gadoterate against reference standards with confirmation of the labelled contrast strength, validated determination of free (uncomplexed) gadolinium and free macrocyclic ligand against defined limits, osmolality, pH, colour and clarity of solution, deliverable volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the glass vial or pre-filled syringe. Certificates of analysis are issued with full traceability back to each gadolinium and DOTA-ligand lot, the primary-packaging lot and the qualified person responsible for release. Because the product is a terminally sterilised diagnostic whose safety depends on the metal staying caged, the assay and the free-gadolinium level are qualified both before and after the sterilisation cycle so the complex's stability to heat is demonstrated rather than simply assumed.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated terminal-sterilisation and filling equipment with 100% inspection, sterilising-grade filtration with filter-integrity testing, dedicated handling with cleaning validation, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because a gadolinium-based contrast agent must deliver its labelled enhancement while keeping free gadolinium and endotoxin very low, we treat the complex assay, the free-gadolinium level, the osmolality, the endotoxin and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under ICH Q1A long-term and accelerated conditions, with the assay and the free-gadolinium level followed across the study, so the solution stays fully complexed and within specification across the labelled shelf life, and the storage instructions on the label are supported by real data.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Gadoterate Meglumine Injection Manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a growing diagnostic-imaging and contrast-media portfolio. For Gadoterate Meglumine Injection specifically, we supply the macrocyclic gadolinium contrast agent as a 0.5 mmol/mL aqueous solution in glass vials of 5, 10, 15 and 20 mL and in pre-filled syringes, under WHO-GMP conditions, with country-specific fill volumes, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier - including the assay, free-gadolinium and free-ligand, osmolality, sterilisation and container-closure data package - ready to hand for registration and tender qualification. Buyers evaluating Gadoterate Meglumine Injection can request the assay, free-gadolinium and accelerated-stability summaries up front, which is often the deciding technical evidence for a contrast agent in radiology and ministry-of-health review, since it is the confirmed complex integrity and a validated sterility assurance that separate a dependable gadoterate from an unreliable one.
Our CDMO services scale cleanly from single-imaging-centre supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability data, free-gadolinium and forced-degradation packages, sterilisation and container-closure reports, and translated package inserts and artwork - including the weight-based dosing table (0.1 mmol/kg), the direction to assess kidney function before use, and the gadolinium-based-contrast-agent class cautions on nephrogenic systemic fibrosis in severe renal impairment and on gadolinium retention - for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Gadoterate Meglumine Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment schedule delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the contrast-agent compounding, filling and sterilisation suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team - practising pharmacists and R&D scientists - can talk through gadolinium and DOTA-ligand sourcing and metal-impurity control, the design of a stable macrocyclic, ionic complex, the strategy for the gadoterate assay and for measuring free (uncomplexed) gadolinium and free ligand, the osmolality and pH windows, the validation of the terminal moist-heat sterilisation cycle, low-endotoxin control, colour, clarity and particulate control, container-closure integrity for both vials and pre-filled syringes, and non-cold-chain shelf-life choices in real detail. For a gadolinium-based contrast agent where complex integrity, free-gadolinium control and sterility directly govern diagnostic quality and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Gadoterate Meglumine Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Gadoterate Meglumine Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated compounding and vial and pre-filled-syringe filling, sterilising-grade filtration, validated terminal moist-heat sterilisation, 100% inspection and continuous environmental monitoring.
Which strengths and presentations of Gadoterate Meglumine Injection do you supply?
Our macrocyclic gadolinium contrast agent is available as a 0.5 mmol/mL (about 279.3 mg/mL) sterile aqueous solution of gadoterate meglumine in glass vials of 5, 10, 15 and 20 mL and in pre-filled syringes, given intravenously. Custom fill volumes, vial and pre-filled-syringe formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Gadoterate Meglumine Injection mainly used for?
Gadoterate Meglumine Injection is used as a contrast medium in magnetic-resonance imaging to enhance the visualisation of the brain, spine and associated tissues, the blood vessels in MR angiography and soft-tissue and whole-body disease. It is a macrocyclic, ionic gadolinium-based contrast agent - the class with the highest complex stability and the lowest risk of releasing free gadolinium - dosed by body weight (typically 0.1 mmol/kg) and given intravenously, with kidney function assessed beforehand. Farbe Firma verifies the assay, free gadolinium, osmolality, particulate matter and endotoxin at release so each unit delivers a stable, sterile contrast solution.
Can Farbe Firma support country-specific registrations for Gadoterate Meglumine Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability data, free-gadolinium and forced-degradation packages, sterilisation and container-closure reports, and translated package inserts and artwork - including the weight-based dosing table and the gadolinium-based-contrast-agent class cautions - for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Gadoterate Meglumine Injection contract manufacturing?
MOQs vary by fill volume, vial or pre-filled-syringe format, label complexity and dossier requirements. For our vial and pre-filled-syringe presentations we accommodate imaging-centre-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments